<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02505399</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/14/7445</org_study_id>
    <nct_id>NCT02505399</nct_id>
  </id_info>
  <brief_title>TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement</brief_title>
  <acronym>TIRATROP</acronym>
  <official_title>TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement: the TIRATROP Study, a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rotational atherectomy (RA) prior to angioplasty is the reference treatment for highly&#xD;
      calcified atherosclerotic coronary lesions. It aims at fragmenting calcium deposits into&#xD;
      microscopic particulates to allow less hazardous coronary revascularization and stenting. The&#xD;
      main drawback associated with the procedure is the subsequent enhancement of platelet&#xD;
      aggregation which promotes the distal embolization of micro-thrombi and atherosclerotic&#xD;
      fragments. In order to limit these complications, a double antiplatelet therapy is required&#xD;
      (generally Clopidogrel + Aspirin) when RA procedures are performed. Clopidogrel inhibits the&#xD;
      protein P2Y12 which is a cornerstone in platelet aggregation. Ticagrelor is a new&#xD;
      antiplatelet agent that provides faster and greater P2Y12 inhibition than Clopidogrel. It is&#xD;
      currently indicated to reduce risk of cardiovascular events in patients hospitalized for&#xD;
      coronary revascularization after an acute coronary syndrome. Ticagrelor has never been&#xD;
      evaluated so far in stable coronary patients treated with rotational atherectomy prior to&#xD;
      angioplasty.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rotational atherectomy (RA) prior to angioplasty is the reference treatment for highly&#xD;
      calcified atherosclerotic coronary lesions. It aims at fragmenting calcium deposits into&#xD;
      microscopic particulates to allow less hazardous coronary revascularization and stenting. The&#xD;
      main drawback associated with the procedure is the subsequent enhancement of platelet&#xD;
      aggregation which promotes the distal embolization of micro-thrombi and atherosclerotic&#xD;
      fragments. In order to limit these complications, a double antiplatelet therapy is required&#xD;
      (generally Clopidogrel + Aspirin) when RA procedures are performed. Clopidogrel inhibits the&#xD;
      protein P2Y12 which is a cornerstone in platelet aggregation. It is characterized by a slow&#xD;
      and variable transformation of a prodrug into an active metabolite and by a remaining risk of&#xD;
      thrombosis and myocardial infarction. Ticagrelor is a new antiplatelet agent that provides&#xD;
      faster and greater P2Y12 inhibition than Clopidogrel. It is currently indicated to reduce&#xD;
      risk of cardiovascular events in patients hospitalized for coronary revascularization after&#xD;
      an acute coronary syndrome. Ticagrelor has never been evaluated so far in stable coronary&#xD;
      patients treated with rotational atherectomy prior to angioplasty.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">May 24, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the curve corresponding to troponin level as a function of time</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Troponin kinetics during the first 24 hours following rotational atherectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>area under the curve corresponding to troponin level as a function of time</measure>
    <time_frame>up to 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequence of clinical events during the in-hospital period</measure>
    <time_frame>One day before the procedure until 36 hours after.</time_frame>
    <description>Major life-threatening bleeding&#xD;
Minor bleeding leading to clinically significant disability&#xD;
Death from any cause,&#xD;
Acute coronary syndrome with or without ST elevation,&#xD;
Ischemic stroke,&#xD;
In-stent thrombosis,&#xD;
Coronary dissection or perforation,&#xD;
Bail-out requiring anti GPIIb-IIIa administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the intervention group, Ticagrelor will be administered orally, according to the following scheme:&#xD;
180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),&#xD;
90 mg the following morning (D Day before rotational atherectomy and angioplasty),&#xD;
90 mg the following evening (D Day after rotational atherectomy and angioplasty),&#xD;
90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the control group, Clopidogrel will be administered orally, according to the following scheme:&#xD;
300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),&#xD;
75 mg the following morning (D Day before rotational atherectomy and angioplasty),&#xD;
0 mg the following evening (D Day after rotational atherectomy and angioplasty),&#xD;
75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <description>Ticagrelor will be administered orally, according to the following scheme:&#xD;
180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),&#xD;
90 mg the following morning (D Day before rotational atherectomy and angioplasty),&#xD;
90 mg the following evening (D Day after rotational atherectomy and angioplasty),&#xD;
90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1).</description>
    <arm_group_label>ticagrelor</arm_group_label>
    <other_name>ticagrelor per os</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Clopidogrel will be administered orally, according to the following scheme:&#xD;
300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),&#xD;
75 mg the following morning (D Day before rotational atherectomy and angioplasty),&#xD;
0 mg the following evening (D Day after rotational atherectomy and angioplasty),&#xD;
75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1).</description>
    <arm_group_label>clopidogrel</arm_group_label>
    <other_name>clopidrogel per os</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Stable coronary patient, or patient presenting with a non ST-elevation acute coronary&#xD;
             syndrome without troponin elevation, or with troponin back to normal,&#xD;
&#xD;
          -  Patient treated with a combination of Aspirin + Clopidogrel before hospitalization at&#xD;
             the study center,&#xD;
&#xD;
          -  Patient with at least one highly calcified coronary lesion eligible for rotational&#xD;
             atherectomy prior to angioplasty,&#xD;
&#xD;
          -  Patient agreed to participate after full information on the study.&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Acute coronary syndrome with ST-elevation,&#xD;
&#xD;
          -  Plasma troponin level higher than 3 times the upper limit of the laboratory,&#xD;
&#xD;
          -  Lesion located on a coronary bypass,&#xD;
&#xD;
          -  Coronary thrombus diagnosed by angiography,&#xD;
&#xD;
          -  Coronary dissection diagnosed by angiography,&#xD;
&#xD;
          -  Left ventricular ejection fraction lower than 30%,&#xD;
&#xD;
          -  Contra-indication to use Ticagrelor or Clopidogrel as listed in the Summary of Product&#xD;
             Characteristics (SmPC, annex 1 &amp; 2):&#xD;
&#xD;
               -  Known hypersensitivity to the active substance or to the excipients,&#xD;
&#xD;
               -  Active pathological bleeding,&#xD;
&#xD;
               -  History of intracranial hemorrhage,&#xD;
&#xD;
               -  Moderate to severe hepatic impairment,&#xD;
&#xD;
               -  Co-administration with a strong cytochrome P450 3A4 inhibitor (e.g. ketoconazole,&#xD;
                  clarithromycin, nefazodone, ritonavir, and atazanavir),&#xD;
&#xD;
          -  Other conditions at increased risk of bleeding:&#xD;
&#xD;
               -  Congenital or acquired coagulation disorder&#xD;
&#xD;
               -  Gastroduodenal bleeding within past 6 months,&#xD;
&#xD;
               -  Recent major trauma or surgery within past 30 days,&#xD;
&#xD;
               -  Concomitant use of fibrinolytics, oral anticoagulation, non-steroidal&#xD;
                  antiinflammatory drugs,&#xD;
&#xD;
          -  Significant anemia,&#xD;
&#xD;
          -  Increased risk of bradycardia,&#xD;
&#xD;
          -  History of asthma or Chronic Obstructive Pulmonary Disease,&#xD;
&#xD;
          -  Uric acid nephropathy,&#xD;
&#xD;
          -  Ischemic stroke within 7 days,&#xD;
&#xD;
          -  Heredity galactose intolerance, Lapp lactase deficiency, or glucose-galactose&#xD;
             malabsorption,&#xD;
&#xD;
          -  Concomitant use of a strong CYP3A4 inducer&#xD;
&#xD;
          -  Concomitant use of CYP3A4 substrates with narrow therapeutic indices (e.g. cisapride,&#xD;
             ergot alkaloids), simvastatin at a dose greater than 40 mg/d,&#xD;
&#xD;
          -  Concomitant use of Selective Serotonin Reuptake inhibitors,&#xD;
&#xD;
          -  Concomitant use of digoxin without close clinical and laboratory monitoring,&#xD;
&#xD;
          -  Contra-indication to use Aspirin,&#xD;
&#xD;
          -  Breast-feeding,&#xD;
&#xD;
          -  Pregnancy,&#xD;
&#xD;
          -  Adult protected by the law,&#xD;
&#xD;
          -  Patient participating in another biomedical research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Didier, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fédération de Cardiologie CHU TOULOUSE</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nîmes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotational Atherectomy</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>thrombosis</keyword>
  <keyword>ticagrelor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

